Levetiracetam
Product Images NDC 68788-7592

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68788-7592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
The figure shows the Responder Rate in Study 1 with a 250% reduction from baseline. The percentages range from 0% to 39.6%, with a statistically significant difference from the placebo. The text also mentions the names Leviaseam and Levieacl with corresponding quantities in ooy.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
The text describes Figure 2 showing the Responder Rate (250% Reduction from Baseline) in Study 2, Period A. It presents a graph with the percentages of patients who responded to the treatment with Levetiracetam 1000 mg/day and Levetiracetam 2000 mg/day, as well as the placebo, indicating that the differences in response rates between Levetiracetam and placebo were statistically significant.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This is a chart displaying the responder rate, which indicates a reduction of over 50% from baseline, in Study 3. The chart compares the responder rates for the group that received a placebo (N=104) and the group that received Levetiracetam 3000 mg/day (N=180). The responder rate for the Levetiracetam group was 45%, which was statistically significant compared to the placebo group's responder rate of 14.4%. However, there was no responder rate indicated for the group who received the placebo or Levetiracetam.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
This is a graph showing the Responder Rate in Study 4 for a Placebo group and a group taking Levetiracetam. The Responder Rate is defined as a 50% reduction from the baseline. The percentages are shown on the y-axis and range from 0% to 50%. The Placebo group had a Responder Rate of 19.6%, while the Levetiracetam group had a Responder Rate of 44.6%. The Levetiracetam group had statistically significant results compared to the placebo group.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
This figure shows the responder rate for patients aged 1 month to less than 4 years in Study 5, with a reduction of over 50% from baseline. The percentages are obscured by illegible characters. The study compared Lovetracatam to placebo, and Lovetracatam was found to be statistically significant.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The text describes a figure labeled as "Figure 6" which shows the responder rate of patients with PGTC seizure frequency per week in Study 7. The figure displays a graph with a range of percentages from 0% to 100%. Two bars are compared, one labeled "Placebo" with 84 patients and the other labeled "Levetiracetam" with 79 patients. The graph shows that the Levetiracetam group had a 72.2% reduction from baseline in PGTC seizure frequency per week, which is statistically significant compared to the placebo. The percentage of patients who responded to Levetiracetam treatment is 45.2%. Approximately 9% of patients did not respond to either treatment.*
FDA Label Image

Levetiracetam Tablet Usp 500mg (Levetiracetam Fig7)

Levetiracetam Tablet Usp 500mg (Levetiracetam Fig7)
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.